Alpers Disease Treatment Global Market Report 2025
상품코드:1825602
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
알파스병 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 5.3%를 나타낼 것으로 예측되고 17억 7,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 연구 자금 증가, 미토콘드리아 장애 유병률 상승, 의료 제공자 간 인식 및 교육 확대, 의약품 증가, 의료 인프라 및 접근성 향상, 환자 옹호 활동 증가 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 유전자 치료 발전, 진단 기술 발전, 의료 기술 발전, 유전공학 발전, 진행 중인 임상 시험 등이 포함됩니다.
향후 5년간 5.3% 성장이라는 예측치는 이 시장에 대한 이전 추정치 대비 0.4% 소폭 하락한 수치입니다. 이러한 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 프랑스와 네덜란드에서 개발된 미토콘드리아 장애 치료제 및 발작 모니터링 장비의 가격 상승을 초래하여 미국 소아 신경학 분야에 부정적 영향을 미칠 수 있습니다. 이는 증상 관리 지연과 희귀질환 치료비 증가로 이어질 것입니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 파급 효과는 더욱 광범위될 전망입니다.
미토콘드리아 장애의 증가하는 유병률은 알퍼스병 치료제 시장을 촉진할 것으로 예상됩니다. 미토콘드리아 장애는 세포 에너지 생산에 필수적인 미토콘드리아 기능 장애로 발생합니다. 이러한 증가는 표적 치료에 대한 수요 증가, 유전학 연구 발전, 진단 능력 향상, 의료진 및 환자 인식 제고에 힘입어 가속화되고 있습니다. 미토콘드리아 장애 시험은 미토콘드리아 기능에 중요한 유전자 변이를 확인함으로써 알퍼스병 진단에 도움을 줍니다. 예를 들어, 2024년 4월에 National Center for Biotechnology Information이 보고한 바와 같이, 2022년 성인에서 mtDNA 관련 미토콘드리아병의 추정 유병률은 10만명당 9.2명이며, 95% 신뢰구간은 6.5-12.7이었습니다. 따라서 미토콘드리아 질환의 증가하는 유병률은 알퍼스병 치료 시장 성장을 촉진할 것으로 예상됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 알파스병 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 알퍼스병 치료 시장 : 성장률 분석
세계의 알파스병 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 알파스병 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 알파스병 치료 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 알파스병 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항경련제
언어치료
물리치료
작업치료
기타 치료
세계의 알파스병 치료 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
임상 검사
분자유전학적 검사
뇌파 검사(EEG)
기타 진단
세계의 알파스병 치료 시장 : 투여량별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
정제
주사제
기타 용량
세계의 알파스병 치료 시장 : 증상별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
두통
치매
발작
경련
간기능장애
실명
뇌 변성증
기타 증상
세계의 알파스병 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
클리닉
병원
기타 최종 사용자
세계의 알파스병 치료 시장, 항경련제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
발프로산
레베티라세탐
라모트리긴
토피라마트
크로나제팜
페노바르비탈
기타
세계의 알퍼스병 치료 시장, 언어치료 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
발음 치료
언어 발달 치료
삼킴 치료
인지 커뮤니케이션 치료
세계의 알파스병 치료 시장, 물리치료 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
운동기능 치료
균형 및 조정 훈련
스트레칭 및 근력 강화 운동
보행 훈련
세계의 알파스병 치료 시장, 작업치료 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소근육 운동 훈련
감각 통합 치료
일상생활 적응 기술
인지 재활
세계의 알파스병 치료 시장, 기타 치료법 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
영양 보급(특수 식이요법)
유전 상담
심리적 지원 및 상담
항산화치료
미토콘드리아 지원 치료
제7장 지역별 및 국가별 분석
세계의 알파스병 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 알파스병 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
알퍼스병 치료 시장 : 경쟁 구도
알퍼스병 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GSK plc
Takeda Pharmaceutical Company Limited
Bausch Health Companies Inc.
UCB SA
Jazz Pharmaceuticals
Aurobindo Pharma
Dr. Reddy's Laboratories
Hikma Pharmaceuticals plc
Lupin Limited
Biocon Limited
Glenmark Pharmaceuticals Limited
Alkem Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Accord Healthcare
Ultragenyx Pharmaceutical Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
알퍼스병 치료 시장(2029년) : 새로운 기회를 제공하는 국가
알퍼스병 치료 시장(2029년) : 새로운 기회를 제공하는 부문
알퍼스병 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Alpers disease, also known as Alpers-Huttenlocher syndrome, is a rare genetic disorder primarily affecting brain function, typically starting in childhood. It is characterized by seizures, developmental delay, and liver dysfunction. Treatment for Alpers disease focuses mainly on symptom management and providing supportive care.
The primary interventions in treating Alpers disease include anticonvulsant medications, speech therapy, physical therapy, occupational therapy, and other supportive measures. Anticonvulsants are prescribed to control seizures and prevent their recurrence in patients with neurological conditions. Diagnosis involves various tests such as laboratory tests, molecular genetic testing, and electroencephalography (EEG). Treatment modalities vary, including tablets, injections, and other forms, aimed at alleviating symptoms such as headaches, dementia, seizures, spasticity, liver dysfunction, blindness, and cerebral degeneration. Treatment can be administered in clinical settings, hospitals, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The alpers disease treatment market research report is one of a series of new reports from The Business Research Company that provides alpers disease treatment market statistics, including the alpers disease treatment industry global market size, regional shares, competitors with alpers disease treatment market share, detailed alpers disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the alpers disease treatment industry. These alpers disease treatment market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The alpers disease treatment market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing awareness and diagnosis rates, improving funding for rare disease research, enhancing patient support networks, increasing regulatory incentives for orphan drug development, and increasing healthcare expenditure.
The alpers disease treatment market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing research funding, rising prevalence of mitochondrial disorders, growing awareness and education among healthcare providers, increasing drug therapies, increasing healthcare infrastructure and accessibility, and rising patient advocacy initiatives. Major trends in the forecast period include advancements in gene therapy, advancements in diagnostic techniques, advancements in healthcare technology, advancements in genetic engineering, and ongoing clinical trials.
The forecast of 5.3% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pediatric neurology by inflating prices of mitochondrial disorder medications and seizure monitoring devices developed in France and Netherlands, resulting in delayed symptom management and higher rare disease care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of mitochondrial disorders is expected to drive growth in the market for Alpers disease treatment. Mitochondrial disorders result from dysfunctions in mitochondria, which are essential for cellular energy production. This rise is fueled by growing demand for targeted therapies, advancements in genetic research, enhanced diagnostic capabilities, and increased awareness among healthcare professionals and patients. Testing for mitochondrial disorders aids in identifying Alpers disease by confirming mutations in genes crucial for mitochondrial function. For instance, as reported by the National Center for Biotechnology Information in April 2024, the estimated prevalence of mtDNA-related mitochondrial disease in adults in 2022 was 9.2 per 100,000 people, with a 95% confidence interval ranging from 6.5 to 12.7. Hence, the increasing prevalence of mitochondrial disorders is poised to stimulate growth in the Alpers disease treatment market.
The growth of the Alpers disease treatment market is expected to be fueled by the increasing availability of personalized medicines. Personalized medicine customizes healthcare decisions, interventions, and treatments to the unique characteristics of each patient. This trend is driven by advancements in genetics, the availability of patient-specific data, and supportive regulatory frameworks. In the context of Alpers disease treatment, personalized medicines enable tailored therapies that target specific genetic mutations and biochemical pathways involved in the disease. This approach can enhance treatment effectiveness and minimize adverse effects. For example, as reported by the Personalized Medicine Coalition in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, up from six approvals in 2022. This underscores the increasing adoption and impact of personalized medicines in driving advancements in treating rare conditions such as Alpers disease. Thus, the expanding availability of personalized medicines is a key driver of growth in the Alpers disease treatment market.
Leading companies in the Alpers disease treatment market are innovating with solutions such as injectable anti-seizure drugs (ASDs) to offer faster and more reliable onset of action compared to oral medications. Injectable ASDs are particularly advantageous for individuals with Alpers disease as they ensure rapid and dependable seizure control, circumvent potential absorption issues in the gastrointestinal tract, provide consistent and effective dosing, and present a precise treatment option for managing this complex neurological condition. For example, Eisai Co. Ltd., a Japan-based pharmaceutical company, introduced FYCOMPA in April 2024, an injectable formulation designed for epilepsy treatment. FYCOMPA is a selective, noncompetitive AMPA receptor antagonist that targets glutamate activity at AMPA receptors on postsynaptic membranes, aiming to reduce neuronal hyper-excitation associated with seizures. Its application in patients with Alpers disease requires careful consideration due to the specific challenges and sensitivities characteristic of the condition.
Major companies operating in the alpers disease treatment market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., UCB S.A., Jazz Pharmaceuticals, Aurobindo Pharma, Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, Lupin Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Accord Healthcare, Ultragenyx Pharmaceutical Inc., Sunovion Pharmaceuticals Inc., Zydus Cadila
North America was the largest region in the alpers disease treatment market in 2024. The regions covered in the alpers disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the alpers disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The alpers disease treatment market consists of revenues earned by entities by providing treatment through medical management, neurological care, genetic counseling, nutritional support, palliative care, and psychological support. The alpers disease treatment market also includes sales of dietary supplements and supportive care. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Alpers Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on alpers disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for alpers disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alpers disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Anticonvulsant Drugs; Speech Therapy; Physical Therapy; Occupational Therapy; Other Treatments
2) By Diagnosis: Laboratory Tests; Molecular Genetic Testing; Electroencephalography (EEG); Other Diagnoses
3) By Dosage: Tablet; Injection; Other Dosages
4) By Symptom: Headache; Dementia; Seizures; Spasticity; Liver Dysfunction; Blindness; Cerebral Degeneration; Other Symptoms
2) By Speech Therapy: Articulation Therapy; Language Development Therapy; Swallowing Therapy; Cognitive Communication Therapy
3) By Physical Therapy: Motor Skill Therapy; Balance And Coordination Training; Stretching And Strengthening Exercises; Gait Training
4) By Occupational Therapy: Fine Motor Skill Training; Sensory Integration Therapy; Adaptive Techniques For Daily Living; Cognitive Rehabilitation
5) By Other Treatments: Nutritional Support (Specialized Diets); Genetic Counseling; Psychological Support And Counseling; Antioxidant Therapy; Mitochondrial Support Therapies
3. Alpers Disease Treatment Market Trends And Strategies
4. Alpers Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Alpers Disease Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Alpers Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Alpers Disease Treatment Market Growth Rate Analysis
5.4. Global Alpers Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Alpers Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Alpers Disease Treatment Total Addressable Market (TAM)
6. Alpers Disease Treatment Market Segmentation
6.1. Global Alpers Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anticonvulsant Drugs
Speech Therapy
Physical Therapy
Occupational Therapy
Other Treatments
6.2. Global Alpers Disease Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Laboratory Tests
Molecular Genetic Testing
Electroencephalography (EEG)
Other Diagnoses
6.3. Global Alpers Disease Treatment Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Injection
Other Dosages
6.4. Global Alpers Disease Treatment Market, Segmentation By Symptom, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Headache
Dementia
Seizures
Spasticity
Liver Dysfunction
Blindness
Cerebral Degeneration
Other Symptoms
6.5. Global Alpers Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End-Users
6.6. Global Alpers Disease Treatment Market, Sub-Segmentation Of Anticonvulsant Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valproic Acid
Levetiracetam
Lamotrigine
Topiramate
Clonazepam
Phenobarbital
Others
6.7. Global Alpers Disease Treatment Market, Sub-Segmentation Of Speech Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Articulation Therapy
Language Development Therapy
Swallowing Therapy
Cognitive Communication Therapy
6.8. Global Alpers Disease Treatment Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Motor Skill Therapy
Balance And Coordination Training
Stretching And Strengthening Exercises
Gait Training
6.9. Global Alpers Disease Treatment Market, Sub-Segmentation Of Occupational Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fine Motor Skill Training
Sensory Integration Therapy
Adaptive Techniques For Daily Living
Cognitive Rehabilitation
6.10. Global Alpers Disease Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nutritional Support (Specialized Diets)
Genetic Counseling
Psychological Support And Counseling
Antioxidant Therapy
Mitochondrial Support Therapies
7. Alpers Disease Treatment Market Regional And Country Analysis
7.1. Global Alpers Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Alpers Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
